# US 2025/0152866 A1 · Dry powder inhaler and system for drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152866 A1
- Document ID: US20250152866A1
- Status: Published application
- Kind: A1
- Application number: 19/025,214
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2008-06-13
- Assignees: MannKind Corporation
- Applicants: MannKind Corporation
- Inventors: Chad C. Smutney; P. Spencer Kinsey; Carl R. Sahi; Benoit Adamo; John M. Polidoro; Scott McLean; Dennis Overfield; Anthony Bryant
- Web page: https://patentgrep.com/patent/US20250152866A1

## CPC

- A61M 15/0045: {using multiple prepacked dosages on a same carrier, e.g. blisters}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 38/1709: {from mammals}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61M 15/0021: {Mouthpieces therefor}
- A61M 15/0023: {retractable}
- A61M 15/0028: {using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up}
- A61M 15/0043: {Non-destructive separation of the package, e.g. peeling}
- A61M 15/0048: {the dosages being arranged in a plane, e.g. on diskettes}
- A61M 15/0086: {Inhalation chambers}
- A61M 15/0091: {mechanically breath-triggered}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61M 2202/064: Powder
- A61M 2205/6081: Colour codes
- A61M 2206/20: having means for promoting or enhancing the flow, actively or passively
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

## Claims

### Claim 1

A single use dry powder inhaler comprising:
a container including a top surface and side wings, and
a mouthpiece including tracks, an inlet, an outlet and a dispensing port,
wherein the side wings are configured to interface with the tracks to allow movement of the container from a containment position to a dosing position, and
wherein the mouthpiece further includes an undersurface configured with a first surface flush with the top surface when in the containment position, and a second surface concave or hollow including the dispensing port above the top surface when in the dosing position.

### Claim 2 (depends on 1)

The single use dry powder inhaler of claim 1, wherein movement of the container is configured to be operated manually.

### Claim 3 (depends on 1)

The single use dry powder inhaler of claim 1, wherein the undersurface includes a bridge.

### Claim 4 (depends on 3)

The single use dry powder inhaler of claim 3, wherein the bridge is configured to be in contact with the container for the movement from the containment position to the dosing position.

### Claim 5 (depends on 4)

The single use dry powder inhaler of claim 4, wherein the movement is translational.

### Claim 6 (depends on 1)

The single use dry powder inhaler of claim 1, wherein the single use dry powder inhaler is disposable.

### Claim 7 (depends on 1)

The single use dry powder inhaler of claim 1, wherein the container is configured to hold a dry powder formulation.

### Claim 8 (depends on 7)

The single use dry powder inhaler of claim 7, wherein the single use inhaler comprises a pre-metered, unit dose comprising the dry powder formulation within the container.

### Claim 9 (depends on 8)

The single use dry powder inhaler of claim 8, wherein the single use inhaler is configured to deliver a single dose of the dry powder formulation.

### Claim 10 (depends on 9)

The single use dry powder inhaler of claim 9, wherein the single dose of the dry powder formulation comprises an active agent.

### Claim 11 (depends on 9)

The single use dry powder inhaler of claim 9, wherein the single dose of the dry powder formulation comprises a pharmaceutical.

### Claim 12 (depends on 9)

The single use dry powder inhaler of claim 9, wherein the single dose is delivered by inhalation.

### Claim 13 (depends on 9)

The single use dry powder inhaler of claim 9, wherein the single dose comprises one or more active agents.

### Claim 14 (depends on 1)

The single use dry powder inhaler of claim 1, wherein the mouthpiece has an elongated shape.

### Claim 15 (depends on 1)

The single use dry powder inhaler of claim 1, wherein the single use dry powder inhaler is breath powered.

### Claim 16 (depends on 1)

The single use dry powder inhaler of claim 1, wherein the single use dry powder inhaler has a total resistance to flow in the dosing position ranging from 0.065 to about 0.200 (√kPa)/liter per minute.

### Claim 17 (depends on 1)

The single use dry powder inhaler of claim 1, wherein the total resistance to flow is relatively constant across a pressure differential range between 0.5 kPa and 7 kPa.

### Claim 18 (depends on 1)

The single use dry powder inhaler of claim 1, wherein the mouthpiece further has an internal volume extending from the inlet to the outlet greater than 0.2 cubic centimeters.

### Claim 19

An inhalation system for delivering a dry powder medicament to a pulmonary tract, comprising:
a container including a top surface, side wings, and a dry powder formulation, and
a mouthpiece including tracks, a first inlet, a second inlet, an outlet, an undersurface, and a dispensing port,
wherein the side wings are configured to interface with the tracks to allow movement of the container from a containment position to a dosing position,
wherein the undersurface is configured with a first surface flush with the top surface when in the containment position and a second surface concave or hollow including the dispensing port above the top surface when in the dosing position, and
wherein the first inlet is in communication with a first air flow pathway and the second inlet is in communication with a second air flow pathway.

### Claim 20 (depends on 19)

The inhalation system of claim 19, wherein the first air flow pathway and the second air flow pathway meet in a substantially perpendicular manner within the mouthpiece.
